Biocon Limited has signed a commercialization agreement with Juno Pharmaceuticals in Canada to market the Indian firm’s “vertically integrated, complex formulation” of liraglutide, a drug-device combination for the treatment and management of type 2 diabetes and obesity.
Biocon And Juno Partner On Liraglutide In Canada
Cites Potential Addressable Canadian Market Of Around $100m For Diabetes Treatment
Biocon has announced a partnership with Juno Pharmaceuticals to market its liraglutide diabetes treatment in Canada, where the firms see a market worth as much as $100m.
